U.S. Markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1970
    +0.0057 (+0.4788%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.3169%)
     
  • USD/JPY

    104.0850
    -0.1650 (-0.1583%)
     
  • BTC-USD

    18,056.37
    +288.31 (+1.62%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Genuine Parts' (GPC) Q3 Earnings Beat, Sales Miss Estimates

Zacks Equity Research
·3 min read

Genuine Parts Company GPC reported third-quarter adjusted diluted earnings of $1.63 per share, surpassing the Zacks Consensus Estimate of $1.48.

Markedly, higher-than-expected revenues from the Industrial Parts segment resulted in this outperformance. Revenues from this segment came in at $1,409 million, beating the Zacks Consensus Estimate of $1,367 million. Moreover, the bottom line came in higher than the year-ago quarter’s profit of $1.39 per share.

This Atlanta-based automotive replacement parts supplier reported net sales of $4,370 million, missing the Zacks Consensus Estimate of $4,459 million. Moreover, the top-line figure comes in lower than the year-ago quarter’s $4525 million, marking a 3.4% decline year over year. This downside resulted from the 1.8% decline in comparable sales and a 4.2% impact from divestitures. These negatives were partially offset by a 1.3% benefit from acquisitions and a 1.3% net impact of foreign currency and other.

Genuine Parts did not issue any guidance for 2020 amid the coronavirus crisis.

Genuine Parts Company Price, Consensus and EPS Surprise

Genuine Parts Company Price, Consensus and EPS Surprise
Genuine Parts Company Price, Consensus and EPS Surprise

Genuine Parts Company price-consensus-eps-surprise-chart | Genuine Parts Company Quote

Segmental Performance

The Automotive segment’s net sales, which have the highest contribution to the company’s revenues, totaled $2,960 million in the reported quarter, up 6% from the prior-year quarter’s $2,792.5 million. The segment’s comparable sales rose 2.2% during the third quarter. The segment’s operating profit increased to $266.1 million in the reported quarter from the year-ago quarter’s $222.6 million.

The Industrial Parts segment’s net sales dropped 18.6% from the year-ago quarter to $1,409.7 million. The segment’s comparable sales declined 9.2% during the reported period. Resultantly, operating profit fell to $125.6 million from the year-earlier quarter’s $137.5 million.

Costs & Cash Position

Total operating expenses edged down 1.34% during the September-end quarter, primarily due to decline in selling, general and administrative (SG&A) expenses. SG&A expenses during third-quarter 2020 slid 3.01% to $1,140.2 million from the $1,175.7 million incurred in third-quarter 2019.

Genuine Parts had cash and cash equivalents worth $900.1 million as of Sep 30, 2020. Long-term debt decreased to $2,700.6 million from the $2,795.9 million recorded in the year-ago period.

Zacks Rank & Other Stocks to Consider

Genuine Parts currently carries a Zacks Rank #2 (Buy). Shares of the company have declined 4%, year to date, while the industry has witnessed a fall of 9.3%.

Some other top-ranked stocks in the same industry are LKQ Corporation LKQ, Dorman Products DORM and SPX Corporation SPXC. Dorman Products and SPK Corporation currently carry a Zacks Rank of 2, while LKQ Corporation flaunts a Zacks Rank of 1 (Strong Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Genuine Parts Company (GPC) : Free Stock Analysis Report
 
Dorman Products, Inc. (DORM) : Free Stock Analysis Report
 
LKQ Corporation (LKQ) : Free Stock Analysis Report
 
SPX Corporation (SPXC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research